Novartis has completed a multi-year transformation into a pure-play innovative medicines company, spinning off its Alcon and Sandoz businesses to focus on high-impact R&D.
The company is heavily investing in next-generation therapeutic platforms, positioning itself as a leader in radioligand therapies, cell and gene therapies, and RNA therapeutics.
The CEO expresses significant concern over the stagnating European pharmaceutical market, which suffers from restrictive policies, contrasting it with the growing and more innovative-friendly markets in the U.S.
Geopolitical shifts are driving a strategy of regionalized manufacturing and R&D, with dedicated capacity being built in the U.S.
and China to ensure supply chain resilience.
12 quotes
Concerns Raised
Stagnating and unfavorable European pharmaceutical market policies that stifle innovation and limit patient access to new medicines.
The risk of geopolitical 'balkanization' of clinical trial data, particularly between the U.S. and China, which could disrupt global drug development.
The inherent difficulty and high failure rate of pharmaceutical R&D, which requires constant innovation to overcome patent cliffs.
Opportunities Identified
Leadership in next-generation therapeutic platforms (radioligand, cell/gene, RNA) with the potential to 'reset' or cure diseases.
The rapidly growing Chinese market, which is now the world's fastest location for clinical trial recruitment and a major source of future growth.
Accelerating drug discovery and improving R&D productivity through strategic partnerships with AI and data science companies like Isomorphic Labs and Palantir.